Molecular Targets for Diagnostics and Therapeutics of Severe Acute Respiratory Syndrome (SARS-CoV)
Identifieur interne : 003074 ( Main/Exploration ); précédent : 003073; suivant : 003075Molecular Targets for Diagnostics and Therapeutics of Severe Acute Respiratory Syndrome (SARS-CoV)
Auteurs : Pravin K. Bhatnagar ; Dipankar Das ; Mavanur R. SureshSource :
- Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques [ 1482-1826 ] ; 2008.
Descripteurs français
- KwdFr :
- Administration par voie nasale, Animaux, Anticorps antiviraux (immunologie), Antigènes viraux (administration et posologie), Antigènes viraux (analyse), Antigènes viraux (immunologie), Canada, Cellules Vero, Protéines de l'enveloppe virale (immunologie), Protéines nucléocapside (immunologie), Protéines virales (administration et posologie), Protéines virales (immunologie), RT-PCR, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (diagnostic), Syndrome respiratoire aigu sévère (génétique), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (traitement médicamenteux), Test ELISA, Tests de neutralisation, Vaccins antiviraux (immunologie), Vaccins antiviraux (usage thérapeutique), Virus du SRAS (génétique), Virus du SRAS (immunologie), Virus du SRAS (isolement et purification), Épitopes (génétique), Épitopes (immunologie).
- MESH :
- administration et posologie : Antigènes viraux, Protéines virales.
- analyse : Antigènes viraux.
- diagnostic : Syndrome respiratoire aigu sévère.
- génétique : Syndrome respiratoire aigu sévère, Virus du SRAS, Épitopes.
- immunologie : Anticorps antiviraux, Antigènes viraux, Protéines de l'enveloppe virale, Protéines nucléocapside, Protéines virales, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS, Épitopes.
- isolement et purification : Virus du SRAS.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Vaccins antiviraux.
- Administration par voie nasale, Animaux, Canada, Cellules Vero, RT-PCR, Syndrome respiratoire aigu sévère, Test ELISA, Tests de neutralisation.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Administration, Intranasal, Animals, Antibodies, Viral (immunology), Antigens, Viral (administration & dosage), Antigens, Viral (analysis), Antigens, Viral (immunology), Canada, Chlorocebus aethiops, Enzyme-Linked Immunosorbent Assay, Epitopes (genetics), Epitopes (immunology), Neutralization Tests, Nucleocapsid Proteins (immunology), Reverse Transcriptase Polymerase Chain Reaction, SARS Virus (genetics), SARS Virus (immunology), SARS Virus (isolation & purification), Severe Acute Respiratory Syndrome (diagnosis), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (genetics), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Vero Cells, Viral Envelope Proteins (immunology), Viral Proteins (administration & dosage), Viral Proteins (immunology), Viral Vaccines (immunology), Viral Vaccines (therapeutic use).
- MESH :
- chemical , administration & dosage : Antigens, Viral, Viral Proteins.
- chemical , analysis : Antigens, Viral.
- chemical , genetics : Epitopes.
- chemical , immunology : Antibodies, Viral, Antigens, Viral, Epitopes, Nucleocapsid Proteins, Viral Envelope Proteins, Viral Proteins, Viral Vaccines.
- chemical , therapeutic use : Viral Vaccines.
- geographic : Canada.
- diagnosis : Severe Acute Respiratory Syndrome.
- drug therapy : Severe Acute Respiratory Syndrome.
- genetics : SARS Virus, Severe Acute Respiratory Syndrome.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- isolation & purification : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- Administration, Intranasal, Animals, Chlorocebus aethiops, Enzyme-Linked Immunosorbent Assay, Neutralization Tests, Reverse Transcriptase Polymerase Chain Reaction, Vero Cells.
Abstract
The large number of deaths in a short period of time due to the spread of severe acute respiratory syndrome (SARS) infection led to the unparalleled collaborative efforts world wide to determine and characterize the new coronavirus (SARS-CoV). The full genome sequence was determined within weeks of the first outbreak by the Canadian group with international collaboration. As per the World Health Organization (WHO), the continual lack of a rapid laboratory test to aid the early diagnosis of suspected cases of SARS makes this area a priority for future research. To prevent deaths in the future, early diagnosis and therapy of this infectious disease is of paramount importance.
This review describes the specific molecular targets for diagnostics and therapeutics of viral infection.
The three major diagnostic methods available for SARS includes viral RNA detection by reverse transcription polymerase chain reaction (RT-PCR), virus induced antibodies by immunofluorescence assay (IFA) or by enzyme linked immunosorbant assay (ELISA) of nucleocapsid protein (NP). The spike glycoprotein of SARS-CoV is the major inducer of neutralizing antibodies. The receptor binding domain (RBD) in the S1 region of the spike glycoprotein contains multiple conformational epitopes that induces highly potent neutralizing antibodies. The genetically engineered attenuated form of the virus or viral vector vaccine encoding for the SARS-CoV spike glycoprotein has been shown to elicit protective immunity in vaccinated animals.
NP is the preferred target for routine detection of SARS-CoV infection by ELISA which is an economical method compared to other methods. The RBD of the spike glycoprotein is both a functional domain for cell receptor binding and also a major neutralizing determinant of SARS-CoV. The progress in evaluating a therapeutic or vaccine would depend on the availability of clinically relevant animal model.
Url:
PubMed: 19203466
PubMed Central: 2678938
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000C18
- to stream Pmc, to step Curation: 000C18
- to stream Pmc, to step Checkpoint: 000E04
- to stream PubMed, to step Corpus: 001965
- to stream PubMed, to step Curation: 001965
- to stream PubMed, to step Checkpoint: 001A85
- to stream Ncbi, to step Merge: 001E44
- to stream Ncbi, to step Curation: 001E44
- to stream Ncbi, to step Checkpoint: 001E44
- to stream Main, to step Merge: 003152
- to stream Main, to step Curation: 003074
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Molecular Targets for Diagnostics and Therapeutics of Severe Acute Respiratory Syndrome (SARS-CoV)</title><author><name sortKey="Bhatnagar, Pravin K" sort="Bhatnagar, Pravin K" uniqKey="Bhatnagar P" first="Pravin K." last="Bhatnagar">Pravin K. Bhatnagar</name></author><author><name sortKey="Das, Dipankar" sort="Das, Dipankar" uniqKey="Das D" first="Dipankar" last="Das">Dipankar Das</name></author><author><name sortKey="Suresh, Mavanur R" sort="Suresh, Mavanur R" uniqKey="Suresh M" first="Mavanur R." last="Suresh">Mavanur R. Suresh</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">19203466</idno><idno type="pmc">2678938</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678938</idno><idno type="RBID">PMC:2678938</idno><date when="2008">2008</date><idno type="wicri:Area/Pmc/Corpus">000C18</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000C18</idno><idno type="wicri:Area/Pmc/Curation">000C18</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000C18</idno><idno type="wicri:Area/Pmc/Checkpoint">000E04</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000E04</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:19203466</idno><idno type="wicri:Area/PubMed/Corpus">001965</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001965</idno><idno type="wicri:Area/PubMed/Curation">001965</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001965</idno><idno type="wicri:Area/PubMed/Checkpoint">001A85</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001A85</idno><idno type="wicri:Area/Ncbi/Merge">001E44</idno><idno type="wicri:Area/Ncbi/Curation">001E44</idno><idno type="wicri:Area/Ncbi/Checkpoint">001E44</idno><idno type="wicri:Area/Main/Merge">003152</idno><idno type="wicri:Area/Main/Curation">003074</idno><idno type="wicri:Area/Main/Exploration">003074</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Molecular Targets for Diagnostics and Therapeutics of Severe Acute Respiratory Syndrome (SARS-CoV)</title><author><name sortKey="Bhatnagar, Pravin K" sort="Bhatnagar, Pravin K" uniqKey="Bhatnagar P" first="Pravin K." last="Bhatnagar">Pravin K. Bhatnagar</name></author><author><name sortKey="Das, Dipankar" sort="Das, Dipankar" uniqKey="Das D" first="Dipankar" last="Das">Dipankar Das</name></author><author><name sortKey="Suresh, Mavanur R" sort="Suresh, Mavanur R" uniqKey="Suresh M" first="Mavanur R." last="Suresh">Mavanur R. Suresh</name></author></analytic><series><title level="j">Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</title><idno type="eISSN">1482-1826</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Antibodies, Viral (immunology)</term><term>Antigens, Viral (administration & dosage)</term><term>Antigens, Viral (analysis)</term><term>Antigens, Viral (immunology)</term><term>Canada</term><term>Chlorocebus aethiops</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Epitopes (genetics)</term><term>Epitopes (immunology)</term><term>Neutralization Tests</term><term>Nucleocapsid Proteins (immunology)</term><term>Reverse Transcriptase Polymerase Chain Reaction</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>SARS Virus (isolation & purification)</term><term>Severe Acute Respiratory Syndrome (diagnosis)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (genetics)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Vero Cells</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Proteins (administration & dosage)</term><term>Viral Proteins (immunology)</term><term>Viral Vaccines (immunology)</term><term>Viral Vaccines (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Antigènes viraux (administration et posologie)</term><term>Antigènes viraux (analyse)</term><term>Antigènes viraux (immunologie)</term><term>Canada</term><term>Cellules Vero</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Protéines nucléocapside (immunologie)</term><term>Protéines virales (administration et posologie)</term><term>Protéines virales (immunologie)</term><term>RT-PCR</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (diagnostic)</term><term>Syndrome respiratoire aigu sévère (génétique)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Test ELISA</term><term>Tests de neutralisation</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins antiviraux (usage thérapeutique)</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (isolement et purification)</term><term>Épitopes (génétique)</term><term>Épitopes (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antigens, Viral</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antigens, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Epitopes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Antigens, Viral</term><term>Epitopes</term><term>Nucleocapsid Proteins</term><term>Viral Envelope Proteins</term><term>Viral Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antigènes viraux</term><term>Protéines virales</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Antigènes viraux</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term><term>Épitopes</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Antigènes viraux</term><term>Protéines de l'enveloppe virale</term><term>Protéines nucléocapside</term><term>Protéines virales</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term><term>Épitopes</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Animals</term><term>Chlorocebus aethiops</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Neutralization Tests</term><term>Reverse Transcriptase Polymerase Chain Reaction</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term><term>Animaux</term><term>Canada</term><term>Cellules Vero</term><term>RT-PCR</term><term>Syndrome respiratoire aigu sévère</term><term>Test ELISA</term><term>Tests de neutralisation</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Purpose</title><p id="P1">The large number of deaths in a short period of time due to the spread of severe acute respiratory syndrome (SARS) infection led to the unparalleled collaborative efforts world wide to determine and characterize the new coronavirus (SARS-CoV). The full genome sequence was determined within weeks of the first outbreak by the Canadian group with international collaboration. As per the World Health Organization (WHO), the continual lack of a rapid laboratory test to aid the early diagnosis of suspected cases of SARS makes this area a priority for future research. To prevent deaths in the future, early diagnosis and therapy of this infectious disease is of paramount importance.</p></sec><sec sec-type="methods" id="S2"><title>Methods</title><p id="P2">This review describes the specific molecular targets for diagnostics and therapeutics of viral infection.</p></sec><sec id="S3"><title>Results</title><p id="P3">The three major diagnostic methods available for SARS includes viral RNA detection by reverse transcription polymerase chain reaction (RT-PCR), virus induced antibodies by immunofluorescence assay (IFA) or by enzyme linked immunosorbant assay (ELISA) of nucleocapsid protein (NP). The spike glycoprotein of SARS-CoV is the major inducer of neutralizing antibodies. The receptor binding domain (RBD) in the S1 region of the spike glycoprotein contains multiple conformational epitopes that induces highly potent neutralizing antibodies. The genetically engineered attenuated form of the virus or viral vector vaccine encoding for the SARS-CoV spike glycoprotein has been shown to elicit protective immunity in vaccinated animals.</p></sec><sec id="S4"><title>Conclusion</title><p id="P4">NP is the preferred target for routine detection of SARS-CoV infection by ELISA which is an economical method compared to other methods. The RBD of the spike glycoprotein is both a functional domain for cell receptor binding and also a major neutralizing determinant of SARS-CoV. The progress in evaluating a therapeutic or vaccine would depend on the availability of clinically relevant animal model.</p></sec></div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Bhatnagar, Pravin K" sort="Bhatnagar, Pravin K" uniqKey="Bhatnagar P" first="Pravin K." last="Bhatnagar">Pravin K. Bhatnagar</name><name sortKey="Das, Dipankar" sort="Das, Dipankar" uniqKey="Das D" first="Dipankar" last="Das">Dipankar Das</name><name sortKey="Suresh, Mavanur R" sort="Suresh, Mavanur R" uniqKey="Suresh M" first="Mavanur R." last="Suresh">Mavanur R. Suresh</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003074 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003074 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:2678938
|texte= Molecular Targets for Diagnostics and Therapeutics of Severe Acute Respiratory Syndrome (SARS-CoV)
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19203466" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |